EA201892277A1 - Противовирусная терапия - Google Patents

Противовирусная терапия

Info

Publication number
EA201892277A1
EA201892277A1 EA201892277A EA201892277A EA201892277A1 EA 201892277 A1 EA201892277 A1 EA 201892277A1 EA 201892277 A EA201892277 A EA 201892277A EA 201892277 A EA201892277 A EA 201892277A EA 201892277 A1 EA201892277 A1 EA 201892277A1
Authority
EA
Eurasian Patent Office
Prior art keywords
viral therapy
hiv
combination
aids
treating
Prior art date
Application number
EA201892277A
Other languages
English (en)
Other versions
EA037601B1 (ru
Inventor
Марк Ричард Андервуд
Original Assignee
Вайв Хелткер Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201892277(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вайв Хелткер Компани filed Critical Вайв Хелткер Компани
Publication of EA201892277A1 publication Critical patent/EA201892277A1/ru
Publication of EA037601B1 publication Critical patent/EA037601B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Настоящее изобретение относится к комбинации для лечения ВИЧ-инфекции, содержащей ингибитор интегразы ВИЧ и ламивудин. Такая комбинация полезна в ингибировании репликации ВИЧ, предупреждении и/или лечении ВИЧ-инфекции и в лечении СПИДа и/или САК (СПИД-ассоциированного комплекса).
EA201892277A 2010-01-27 2011-01-24 Комбинация для лечения вич-инфекции EA037601B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27

Publications (2)

Publication Number Publication Date
EA201892277A1 true EA201892277A1 (ru) 2019-03-29
EA037601B1 EA037601B1 (ru) 2021-04-20

Family

ID=44319704

Family Applications (4)

Application Number Title Priority Date Filing Date
EA202190473A EA202190473A3 (ru) 2010-01-27 2011-01-24 Противовирусная терапия
EA201290583A EA025176B1 (ru) 2010-01-27 2011-01-24 Комбинация для лечения вич-инфекции
EA201892277A EA037601B1 (ru) 2010-01-27 2011-01-24 Комбинация для лечения вич-инфекции
EA201690872A EA032868B1 (ru) 2010-01-27 2011-01-24 Комбинация для лечения вич-инфекции

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA202190473A EA202190473A3 (ru) 2010-01-27 2011-01-24 Противовирусная терапия
EA201290583A EA025176B1 (ru) 2010-01-27 2011-01-24 Комбинация для лечения вич-инфекции

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201690872A EA032868B1 (ru) 2010-01-27 2011-01-24 Комбинация для лечения вич-инфекции

Country Status (45)

Country Link
US (12) US20120295898A1 (ru)
EP (6) EP3127542B1 (ru)
JP (8) JP2013518107A (ru)
KR (4) KR101964923B1 (ru)
CN (2) CN102791129B (ru)
AP (1) AP3551A (ru)
AU (1) AU2011209788C1 (ru)
BR (1) BR112012018670A2 (ru)
CA (4) CA2967453C (ru)
CL (1) CL2012002080A1 (ru)
CO (1) CO6602152A2 (ru)
CR (1) CR20120423A (ru)
CY (4) CY1116509T1 (ru)
DK (4) DK3494972T3 (ru)
DO (2) DOP2012000205A (ru)
EA (4) EA202190473A3 (ru)
EC (1) ECSP12012106A (ru)
ES (3) ES2543066T3 (ru)
FI (1) FI3494972T3 (ru)
FR (1) FR18C1043I2 (ru)
HK (3) HK1250335A1 (ru)
HR (3) HRP20150770T1 (ru)
HU (4) HUE037812T2 (ru)
IL (5) IL221007A (ru)
LT (4) LT3127542T (ru)
LU (1) LUC00090I2 (ru)
MA (1) MA34002B1 (ru)
ME (2) ME03058B (ru)
MX (4) MX356891B (ru)
MY (1) MY188334A (ru)
NO (2) NO2932970T3 (ru)
NZ (4) NZ627827A (ru)
PE (2) PE20160180A1 (ru)
PH (2) PH12016500195B1 (ru)
PL (3) PL2531027T3 (ru)
PT (4) PT3127542T (ru)
RS (4) RS57323B1 (ru)
SG (3) SG10201509476RA (ru)
SI (4) SI2531027T1 (ru)
SM (1) SMT201500177B (ru)
TN (1) TN2012000376A1 (ru)
TR (1) TR201807704T4 (ru)
UA (1) UA105556C2 (ru)
WO (1) WO2011094150A1 (ru)
ZA (1) ZA201205586B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57323B1 (sr) 2010-01-27 2018-08-31 Viiv Healthcare Co Antivirusna terapija
BR112015006558A2 (pt) 2012-10-23 2017-07-04 Cipla Ltd composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar doenças causadas por retrovírus
KR102040007B1 (ko) 2012-12-21 2019-11-05 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
CA2897137A1 (en) 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
ES2645192T3 (es) 2013-07-12 2017-12-04 Gilead Sciences, Inc. Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
NO2865735T3 (ru) 2013-07-12 2018-07-21
MA38922A3 (fr) 2013-09-27 2018-11-30 Merck Sharp & Dohme Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih
IN2014MU00916A (ru) 2014-03-20 2015-09-25 Cipla Ltd
CA2950911C (en) 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
NO2717902T3 (ru) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
US10189860B2 (en) 2014-07-29 2019-01-29 Lek Pharmaceuticals D.D. Hydrates of dolutegravir sodium
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3736274A1 (en) 2015-04-02 2020-11-11 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2017029226A1 (en) 2015-08-14 2017-02-23 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
JP2020528413A (ja) * 2017-07-21 2020-09-24 ヴィーブ ヘルスケア カンパニー Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
CN111107850A (zh) 2017-07-21 2020-05-05 Viiv保健公司 用于治疗hib感染和aids的方案
MX2020003377A (es) * 2017-10-13 2020-09-28 Viiv Healthcare Co Formulacion de tableta farmaceutica de dos capas.
TW202204356A (zh) 2019-03-22 2022-02-01 美商基利科學股份有限公司 橋鍵聯三環胺甲醯吡啶酮化合物及其醫藥用途
CN114901363A (zh) * 2020-01-09 2022-08-12 华盛顿大学 长效治疗剂组合物及其方法
WO2021173522A1 (en) 2020-02-24 2021-09-02 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
EP4321217A3 (en) 2021-01-19 2024-04-10 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
WO2023164293A1 (en) * 2022-02-28 2023-08-31 Jericho Sciences, Llc Methods for viral infections

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (ru) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Способ лечения ретровирусных инфекций
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
NZ333099A (en) * 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
EP1063888A1 (en) 1998-03-27 2001-01-03 The Regents of the University of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (ru) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтическая композиция эфавиренца в сочетании с ингредиентами, обеспечивающими распад таблеток, и способ изготовления быстрорастворимых таблеток и капсул эфавиренца
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
MXPA02007426A (es) 2000-01-31 2003-10-14 Cook Biotech Inc Valvulas restringidas y uso de las mismas.
PT1377556E (pt) 2001-04-10 2007-06-06 Pfizer Ltd Derivados de pirazole para tratamento do hiv
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
AR040242A1 (es) 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
NZ535817A (en) 2002-06-27 2006-11-30 Medivir Ab Synergistic interaction of abacavir and alovudine
PT1583542E (pt) * 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
KR20070002006A (ko) * 2004-02-11 2007-01-04 스미스클라인 비참 코포레이션 Ｈｉｖ 인테그라제 억제제
SI1742642T1 (sl) * 2004-04-14 2009-04-30 Gilead Sciences Inc Fosfonatni analogi inhibitorskih spojin HIV integraze
EP3287130A1 (en) * 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
CN101022812A (zh) 2004-08-23 2007-08-22 特瓦制药工业有限公司 固体和晶体伊班膦酸钠及其制备方法
WO2006024668A1 (en) 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
ATE414092T1 (de) 2004-09-17 2008-11-15 Idenix Pharmaceuticals Inc Phosphoindole als hiv-inhibitoren
EP1853604A4 (en) 2005-03-04 2010-02-24 Smithkline Beecham Corp CHEMICAL COMPOUNDS
MX302718B (es) 2005-04-28 2012-08-27 Smithkline Beecham Corp Derivado de carbamoilpiridona policiclico que tiene actividad inhibidora de la integrasa de hiv.
CN101212903B (zh) * 2005-04-28 2013-07-24 史密丝克莱恩比彻姆公司 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
AU2006332664B2 (en) * 2005-12-30 2013-03-14 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of HIV integrase inhibitors
CN101336107A (zh) * 2005-12-30 2008-12-31 吉里德科学公司 改善hiv整合酶抑制剂的药物动力学的方法
KR101501475B1 (ko) * 2006-01-20 2015-03-19 얀센 알 앤드 디 아일랜드 Ｔｍｃ２７８을 이용한 ｈｉｖ 감염의 장기간 요법
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
US20090306112A1 (en) 2006-07-21 2009-12-10 Gilead Sciences, Inc. Antiviral protease inhibitors
EP2078029B1 (en) 2006-09-29 2014-05-14 IDENIX Pharmaceuticals, Inc. Enantiomerically pure phosphoindole as hiv inhibitor
TW200835693A (en) 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
NZ579802A (en) 2007-02-23 2012-04-27 Gilead Sciences Inc Compounds for improving the efficacy of other drugs
WO2009005674A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Novel hiv reverse transcriptase inhibitors
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
AR067412A1 (es) 2007-07-06 2009-10-07 Gilead Sciences Inc Moduladores de propiedades farmaceuticas de productos terapeuticos
CN101743006B (zh) * 2007-07-12 2013-09-11 泰博特克药品公司 (e)4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的晶型
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
US8466177B2 (en) 2007-11-01 2013-06-18 The Uab Research Foundation Treating and preventing viral infections
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
MX2010007375A (es) * 2008-01-03 2010-09-30 Virochem Pharma Inc Nuevos derivados de lupano.
EP2240504A1 (en) 2008-01-03 2010-10-20 Virochem Pharma Inc. Novel c-21-keto lupane derivatives preparation and use thereof
AU2008346823B2 (en) 2008-01-04 2015-03-12 Gilead Sciences, Inc. Inhibitors of cytochrome P450
AU2009214779A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
EP2320908B9 (en) * 2008-07-25 2014-06-18 VIIV Healthcare Company Dolutegravir Prodrugs
SG171308A1 (en) * 2008-12-11 2011-07-28 Shionogi & Co Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
SG171731A1 (en) 2008-12-11 2011-07-28 Glaxosmithkline Llc Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
RS57323B1 (sr) 2010-01-27 2018-08-31 Viiv Healthcare Co Antivirusna terapija
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
CN103402516B (zh) 2010-06-17 2018-01-30 富津世生物技术有限公司 用作抗病毒药物的化合物、组合物及使用方法

Also Published As

Publication number Publication date
LT2932970T (lt) 2018-06-25
CY2018029I1 (el) 2019-07-10
CA2967453A1 (en) 2011-08-04
ES2543066T3 (es) 2015-08-14
JP2013518107A (ja) 2013-05-20
PT3127542T (pt) 2018-11-26
KR20120128640A (ko) 2012-11-27
US20200230147A1 (en) 2020-07-23
US10426780B2 (en) 2019-10-01
LT3494972T (lt) 2024-03-12
EP3351249A1 (en) 2018-07-25
HK1250335A1 (zh) 2018-12-14
PE20121524A1 (es) 2012-12-03
EP3494972B1 (en) 2023-12-13
WO2011094150A1 (en) 2011-08-04
EA202190473A2 (ru) 2021-06-30
CY1116509T1 (el) 2017-03-15
CL2012002080A1 (es) 2012-11-30
EP2531027A4 (en) 2013-07-03
CA2787691C (en) 2018-07-17
AU2011209788C1 (en) 2014-08-28
SI3494972T1 (sl) 2024-03-29
FI3494972T3 (fi) 2024-03-01
LTC2932970I2 (lt) 2022-04-25
IL245182B (en) 2018-04-30
EP2932970B1 (en) 2018-03-21
DK2531027T3 (en) 2015-07-20
SG10201509476RA (en) 2015-12-30
ECSP12012106A (es) 2013-05-31
IL257267A (en) 2018-03-29
IL267658A (en) 2019-08-29
US11234985B2 (en) 2022-02-01
EA201690872A2 (ru) 2016-08-31
AP2012006445A0 (en) 2012-08-31
EP3127542B1 (en) 2018-08-22
KR20170078868A (ko) 2017-07-07
KR101964923B1 (ko) 2019-04-02
JP2017008087A (ja) 2017-01-12
US20150238496A1 (en) 2015-08-27
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
NO2018036I1 (no) 2018-10-15
MX367937B (es) 2019-09-12
PH12018502489A1 (en) 2020-06-15
EA201690872A3 (ru) 2016-12-30
CA3060290C (en) 2022-07-12
AU2011209788B2 (en) 2014-02-06
JP2021091705A (ja) 2021-06-17
CA3003988A1 (en) 2011-08-04
HUE040554T2 (hu) 2019-03-28
BR112012018670A2 (pt) 2018-02-06
PL2932970T3 (pl) 2018-08-31
MY188334A (en) 2021-11-30
MX356891B (es) 2018-06-19
IL245182A0 (en) 2016-06-30
HUE037812T2 (hu) 2018-09-28
SMT201500177B (it) 2015-09-07
HUE026849T2 (en) 2016-08-29
ES2670811T3 (es) 2018-06-01
LTPA2018013I1 (lt) 2018-11-12
EA201290583A1 (ru) 2013-04-30
AU2011209788A1 (en) 2012-08-16
JP2023085431A (ja) 2023-06-20
DK3127542T3 (en) 2018-11-12
MA34002B1 (fr) 2013-02-01
KR20180078358A (ko) 2018-07-09
CY1120457T1 (el) 2019-07-10
MX367938B (es) 2019-09-12
LT3127542T (lt) 2018-11-26
CA2967453C (en) 2018-07-17
KR101830715B1 (ko) 2018-04-04
PT2932970T (pt) 2018-06-08
EA202190473A3 (ru) 2021-12-31
CA2787691A1 (en) 2011-08-04
PL3127542T3 (pl) 2019-03-29
HRP20150770T1 (hr) 2015-08-28
CY1121040T1 (el) 2019-12-11
RS57728B1 (sr) 2018-12-31
KR20160111536A (ko) 2016-09-26
HRP20180855T1 (hr) 2018-06-29
CR20120423A (es) 2012-11-22
EP2932970A1 (en) 2015-10-21
PE20160180A1 (es) 2016-05-04
ZA201205586B (en) 2014-01-29
US20170281636A1 (en) 2017-10-05
CN105311033A (zh) 2016-02-10
PT3494972T (pt) 2024-02-12
IL281959A (en) 2021-05-31
US20160339033A1 (en) 2016-11-24
PT2531027E (pt) 2015-09-16
CN105311033B (zh) 2019-05-07
DK3494972T3 (da) 2024-01-29
EP3494972A1 (en) 2019-06-12
NZ627826A (en) 2016-01-29
US20160199379A1 (en) 2016-07-14
US20170079982A1 (en) 2017-03-23
IL221007A0 (en) 2012-09-24
CN102791129A (zh) 2012-11-21
FR18C1043I2 (fr) 2019-10-11
DOP2021000147A (es) 2022-01-16
EA025176B1 (ru) 2016-11-30
EP2531027B1 (en) 2015-05-06
HK1209629A1 (en) 2016-04-08
US20170216284A1 (en) 2017-08-03
TR201807704T4 (tr) 2018-06-21
SG10201707183TA (en) 2017-10-30
UA105556C2 (ru) 2014-05-26
EP4316599A2 (en) 2024-02-07
NO2932970T3 (ru) 2018-08-18
PL2531027T3 (pl) 2016-01-29
RS54123B1 (en) 2015-12-31
ME03058B (me) 2019-01-20
JP2016145204A (ja) 2016-08-12
DK2932970T3 (en) 2018-05-28
FR18C1043I1 (ru) 2018-11-30
EP4316599A3 (en) 2024-04-10
CN102791129B (zh) 2015-09-30
TN2012000376A1 (en) 2014-01-30
SI3127542T1 (sl) 2018-11-30
IL257267B (en) 2019-08-29
CA3003988C (en) 2020-01-07
US20180098992A1 (en) 2018-04-12
IL281959B (en) 2021-12-01
SI2531027T1 (sl) 2015-08-31
IL267658B (en) 2021-04-29
JP6268386B2 (ja) 2018-01-31
ES2688925T3 (es) 2018-11-07
NZ627824A (en) 2016-02-26
ME02182B (me) 2015-10-20
US20210401850A1 (en) 2021-12-30
NZ601319A (en) 2014-08-29
JP2019167371A (ja) 2019-10-03
HUS1800042I1 (hu) 2018-11-28
CA3060290A1 (en) 2011-08-04
US20120295898A1 (en) 2012-11-22
JP2022071126A (ja) 2022-05-13
CY2018029I2 (el) 2019-07-10
EP2531027A1 (en) 2012-12-12
EP3127542A1 (en) 2017-02-08
SI2932970T1 (en) 2018-07-31
EA037601B1 (ru) 2021-04-20
NZ627827A (en) 2016-02-26
CO6602152A2 (es) 2013-01-18
RS65183B1 (sr) 2024-03-29
HK1179522A1 (en) 2013-10-04
HRP20181531T1 (hr) 2018-11-16
DOP2012000205A (es) 2012-10-15
IL221007A (en) 2016-06-30
US20170119777A1 (en) 2017-05-04
JP2018127473A (ja) 2018-08-16
MX2012008774A (es) 2012-08-17
PH12016500195A1 (en) 2016-12-05
AP3551A (en) 2016-01-18
EA032868B1 (ru) 2019-07-31
PH12016500195B1 (en) 2016-12-05
US20180200254A1 (en) 2018-07-19
KR101883750B1 (ko) 2018-07-31
LUC00090I2 (ru) 2019-01-08

Similar Documents

Publication Publication Date Title
EA201892277A1 (ru) Противовирусная терапия
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
EA201391108A1 (ru) Лечение липодистрофии
EA201691931A1 (ru) 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы
EA201590358A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201291300A1 (ru) Производные нафт-2-илуксусной кислоты для лечения спида
UA114006C2 (xx) Похідні 5-фенокси-3h-піримідин-4-ону і їхнє застосування як інгібіторів зворотної транскриптази віл
UA111841C2 (uk) Сполуки бензотіазолу та їх фармацевтичне застосування
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
EA201001508A1 (ru) Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
GEP20227353B (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
EP2555798A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSIONS
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201171186A1 (ru) Сокристалл этравирина и никотинамида
EA201290852A1 (ru) Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель
IN2011CH03893A (ru)
EA201990295A1 (ru) Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
EA201370056A1 (ru) Интерферониндуцирующее средство для лечения острых респираторных вирусных инфекций (орви)
TR201110202A2 (tr) Hepatit B ve/veya AIDS tedavisinde antiretroviral farmasötikler.

Legal Events

Date Code Title Description
ND4A Extension of term of a eurasian patent